Denise A. Yardley, MD, discusses the promise of CDK4&6 inhibitors in estrogen receptor (ER)-positive breast cancer, as well as the potential with immunotherapy agents.
Laura J. van’t Veer, PhD, discusses determining more accurate methods of treatment for patients with early- and late-stage breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.
Published: November 3rd 2017 | Updated: April 17th 2020
Published: November 29th 2017 | Updated: April 17th 2020
Published: December 19th 2017 | Updated: April 18th 2020